TOCILIZUMAB, Tarlatamab, DEXAMETHASONE, Placebo for Tarlatamab (AMG-757), PARACETAMOL , ELECTROLYTES , PREDNISOLONE , Tarlatamab, VASOPRESSIN (ARGIPRESSIN) , SILTUXIMAB
20230016
Phase 3 small_molecule active
Quick answer
TOCILIZUMAB, Tarlatamab, DEXAMETHASONE, Placebo for Tarlatamab (AMG-757), PARACETAMOL , ELECTROLYTES , PREDNISOLONE , Tarlatamab, VASOPRESSIN (ARGIPRESSIN) , SILTUXIMAB for Limited-Stage Small-Cell Lung Cancer (LS SCLC) is a Phase 3 program (small_molecule) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen Technology (Ireland) UC
- Indication
- Limited-Stage Small-Cell Lung Cancer (LS SCLC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active